Video: Positive trends for outcomes in uric acid stroke trial gives optimism

The outcomes in a double-blind, randomized, placebo-controlled trial in which uric acid was added to thrombolytic therapy for acute ischemic stroke were not statistically significant, but the positive trend seen in the outcomes indicates that a larger trial may show significant benefits, Dr. Angel Chamorro of the Hospital Clinic of the University of Barcelona (Spain) said at the International Stroke Conference.

The outcomes in a double-blind, randomized, placebo-controlled trial in which uric acid was added to thrombolytic therapy for acute ischemic stroke were not statistically significant, but the positive trend seen in the outcomes indicates that a larger trial may show significant benefits, Dr. Angel Chamorro of the Hospital Clinic of the University of Barcelona (Spain) said at the International Stroke Conference.

The outcomes in a double-blind, randomized, placebo-controlled trial in which uric acid was added to thrombolytic therapy for acute ischemic stroke were not statistically significant, but the positive trend seen in the outcomes indicates that a larger trial may show significant benefits, Dr. Angel Chamorro of the Hospital Clinic of the University of Barcelona (Spain) said at the International Stroke Conference.